10 Best Life Sciences Stocks To Invest In Right Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Steris (NYSE: STE  ) �-- a manufacturer of infection prevention, contamination control, and surgical support products for the health-care industry -- jumped as much as 10% after reporting better-than-expected fourth-quarter results.

So what: For the quarter, Steris' shareholders witnessed revenue increase by 10% to $428.2 million as EPS shrank modestly to $0.70 from $0.76 in the year-ago period. Although Steris blamed European weakness and the medical device excise tax for its weaker bottom-line results, both figures topped the $406 million in revenue and $0.65 in EPS that the Street had been expecting. The biggest boost came from the company's life sciences segment, which saw operating income grow by 14%. For the upcoming year, Steris issued guidance calling for revenue growth of 8%-10% (implying $1.62 billion to $1.65 billion) and EPS of $2.47-$2.60. Current consensus estimates are for revenue of $1.57 billion and EPS of $2.49.

Top 5 Dow Dividend Companies To Watch For 2015: FactSet Research Systems Inc. (FDS)

FactSet Research Systems Inc. provides financial and economic information to investment community worldwide. FactSet offers fundamental financial data on various companies, analytical applications, and client services to the portfolio managers, research and performance analysts, risk managers, marketing professionals, sell-side equity research professionals, investment bankers, and fixed income professionals. The company?s applications provide users access to company analysis, multicompany comparisons, industry analysis, company screening, portfolio analysis, predictive risk measurements, alphatesting, portfolio optimization and simulation, news and quotes, and tools to value and analyze fixed income securities and portfolios. FactSet combines commercial databases, including content regarding companies and securities from various markets into a single online platform of information and analytics. The company?s solutions for investment management professionals include analy zing market, sector, and fundamental series; offering applications for portfolio attribution, risk management, and quantitative analysis; building quant models and calculating risk; analyzing the nuances of the debt-driven market; viewing event transcripts and corporate event calendars; researching and analyzing companies, benchmarks, debt instruments, and economic series; integrating the client?s own data, such as portfolio holdings and research notes; and creating reports and presentations. FactSet?s solutions for investment banking professionals comprise creating models and presentations; tracking market performance and headlines; providing deal analytic and corporate governance servies; researching on public and private companies; auditing financials underlying SEC filings and annual reports; and providing access to reports via wireless handheld device. The company was founded in 1978 and is headquartered in Norwalk, Connecticut.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Top Headline
  FactSet Research Systems (NYSE: FDS) reported a 4.8% rise in its fiscal first-quarter profit and issued a weak earnings guidance for the current quarter.

• [By alicet236]

  FactSet Research Systems Inc. (FDS): CEO & Chairman Philip A. Hadley Sold 115,000 Shares

  CEO and Chairman of FactSet Research Systems Inc. (FDS) Philip A. Hadley sold 115,000 shares on 01/15/2014 at an average price of $107.61. FactSet Research Systems Inc. was founded as a Delaware corporation in 1978. Factset Research Systems Inc. has a market cap of $4.57 billion; its shares were traded at around $106.88 with a P/E ratio of 23.50 and P/S ratio of 5.43. The dividend yield of Factset Research Systems Inc. stocks is 1.27%. Factset Research Systems Inc. had an annual average earnings growth of 14.30% over the past 10 years. GuruFocus rated Factset Research Systems Inc. the business predictability rank of 3.5-star.

• [By Jake L'Ecuyer]

  Top Headline
  FactSet Research Systems (NYSE: FDS) reported a 5 percent rise in its fiscal fourth-quarter earnings. FactSet Research's quarterly profit surged to $51 million, or $1.16 per share, from $48.5 million, or $1.08 per share, in the year-ago period. Excluding one-time items, its adjusted earnings came in at $1.20 per share, versus analysts' estimates of $1.21 per share. Its revenue rose 5.6 percent to $219.3 million. FactSet Research had expected earnings of $1.18 to $1.21 per share on revenue of $218 million to $221 million. For the current quarter, FactSet Research expects earnings of $1.21 to $1.24 per share on revenue of $222 million to $225 million. However, analysts were projecting a profit of $1.23 per share on revenue of $224 million.

10 Best Life Sciences Stocks To Invest In Right Now: Powershares Qqq Trust Series 1 (QQQ)

PowerShares QQQ Trust, Series 1, formerly The NASDAQ-100 Trust, Series 1, is a unit investment trust that issues securities called Nasdaq-100 Index Tracking Stock. The Trust holds all of the component securities of the Nasdaq-100 Index. The Trust's investment objective is to provide investment results that generally correspond to the price and yield performance of the Nasdaq-100 Index.

The Trust was created to provide investors with the opportunity to purchase units of beneficial interest in the Trust representing proportionate undivided interests in the portfolio of securities held by the Trust, which consists of substantially all of the securities, in substantially the same weighting, as the component securities of the Nasdaq-100 Index. Nasdaq Global Funds, Inc. is the sponsor of the Trust and The Bank of New York is the trustee of the Trust.

Advisors' Opinion:

• [By Tom Aspray]

  The Powershares QQQ Trust (QQQ) is clearly the leader, up over 200%, which is over 20% better than the iShares Russell 2000 (IWM), which is up 178%. The small caps have done over 40% better than the large cap Spyder Trust (SPY) but this performance does not include dividends, which would narrow the gap considerably. The SPDR Dow Jones Industrials (DIA) has continued to lag as its price is up just 120% during the bull market.

• [By Markos Kaminis]

  The Fed Chairman handled the questions well enough, indicating that one theorized future action would not mean that a series of tapering operations would follow. In other words, if the Fed were to stop its purchases in the treasury market, it might not mean it would do the same in the mortgage-backed securities market, and it certainly did not mean the Fed would be raising interest rates anytime soon. After all, deflation is the current issue of concern, not inflation. But the meeting minutes showed some discussion among the members about monetary policy, which is (surprisingly it seems to the market) what they discuss at these meetings. I suppose out of boredom or perhaps the duties of the job, somebody always has to bring up change and the prospect of raising rates. Woe, said the market; we do not want any of that! It drove turbulence in the performance of the broader indexes and the ETFs that mimic them, with the SPDR S&P 500 (SPY), SPDR Dow Jones Industrial Average (DIA) and the PowerShares QQQ (QQQ) each turning downward since the May 22nd events.

• [By Dan Caplinger]

  Since then, several other indexes had been less hesitant to add Facebook to their ranks. Russell's indexes were among the first to include Facebook as a constituent, and as various lockup provisions expired to expand the stock's float, Russell responded earlier this year by boosting the social-media giant's weighting in several key indexes. The Nasdaq 100 brought on Facebook as a member a year ago, giving shareholders in PowerShares QQQ (NASDAQ: QQQ  ) the same conundrum that S&P index fund investors face today.

10 Best Life Sciences Stocks To Invest In Right Now: Corewafer Industries Inc (WAFR)

COREwafer Industries, Inc., formerly Action Products International, incorporated on January 7, 1981, is a holding company that acquires or merges with companies with growth opportunity. The company's business model is to bring together companies that deliver complimentary technology and services. The Company�� products and services include Logistics & Transportation and Software & Technology.

Logistics & Transportation

Northeast Expedite Logistics, LLC (NEEL) is a provider of global logistics services, which includes a domestic service center and exclusive and non-exclusive agents. The Company�� customers include retail and wholesale, electronics, and manufacturing companies around the world. With industrial production increasing year-over-year, the shortage of qualified drivers and trusted shipping partners is apparent in mid-markets for local deliveries. As the economy improves, orders for delivery and logistics. The Company provide foundational shipping and coordination services between suppliers and destination businesses and warehouses, and the Company operate efficiently through cloud based tracking.

Software & Technology

The Company has a particular focus within technology on semiconductor testing. To enable success of its software and technology vertical, the Company acquired Core Wafer Systems, Inc. Core Wafer Systems, Inc., a Nevada corporation, creates software, software algorithms, and hardware that are used in the testing and data mining of the commonly used semiconductor components. Core Wafer ensures these components, created by semiconductor manufacturers, leave the factory in a working state after having been tested. Core Wafer helps ensure that products are manufactured within specification and won't suddenly fail for the end consumer. The Company is working to integrate the operations and financial records of Core Wafer with those of the Company.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks COREwafer Industries Inc (OTCMKTS: WAFR), DC Brands International, Inc (OTCMKTS: HRDN) and PV Enterprises International (OTCMKTS: PVEC) surged 82.86%, 33.33% and 25%, respectively, last Friday ��meaning investors or traders got a nice Christmas present. Moreover, these small cap stocks have been the subject of minimal paid stock promotions. But will these three small cap stocks continue to deliver a good performance into and after the holidays? Here is a quick reality check before you get overly excited:

10 Best Life Sciences Stocks To Invest In Right Now: Gulfport Energy Corporation(GPOR)

Gulfport Energy Corporation engages in the exploration, development, and production of oil and natural gas properties. Its principal properties are located in the Louisiana Gulf Coast, in west Texas in the Permian Basin and in western Colorado in the Niobrara Formation. The company also holds acreage position in the Alberta oil sands in Canada; and interests in entities that operate in southeast Asia, including the Phu Horm gas field in Thailand, as well as leasehold interests in the Utica Shale in eastern Ohio. As of December 31, 2011, it had 19.4 million barrels of oil equivalent of proved reserves. The company is headquartered in Oklahoma City, Oklahoma.

Advisors' Opinion:

• [By Tyler Crowe]

  O-H-I-O
  While there are many shale formations in the U.S. producing high amounts of condensate, one could benefit from moving condensate to Canada more than the others; the Utica formation. While the Utica hasn't turned out to be the oil play some were hoping it would be, the most lucrative wells in the region are being drilled in what is known as the "wet gas" region of the play. In this region, Utica-heavy operators Chesapeake Energy (NYSE: CHK  ) and Gulfport Energy (NASDAQ: GPOR  ) have focused much of their attention in this region, because it is believed to generate the highest rate of return for drillers.

• [By Arjun Sreekumar]

  Infrastructure additions also bode well for Gulfport Energy (NASDAQ: GPOR  ) , a company highly levered to the play. In fact, Gulfport is plowing the majority of its capital budget toward developing its Utica acreage, with quite impressive well results thus far. Improved infrastructure should also provide a boost to Rex Energy (NASDAQ: REXX  ) , which is allocating nearly a third of its roughly $255 million capital budget for the year toward developing its assets in the Utica.

• [By Ben Levisohn]

  Shares of Penn Virginia have gained 8.5% to $14.01 at $3:08 p.m., putting it up 49% so far this year. Shares of EQT Corp. (EQT) have ticked up 0.2% to $100.23, while Devon Energy (DVN) has risen 0.5% to $64.54, EOG Resources (EOG) has advanced 0.6% to $179.84 and Gulfport Energy (GPOR) is up 0.1% at $64.87.

10 Best Life Sciences Stocks To Invest In Right Now: Steinway Musical Instruments Inc. (LVB)

Steinway Musical Instruments, Inc., through its subsidiaries, designs, manufactures, markets, and distributes musical instruments in the United States and internationally. The company operates in two segments, Pianos and Band & Orchestral Instruments. The Pianos segment offers pianos under Steinway & Sons, Boston, and Essex brands; and engages in online music retailing business. This segment sells its products to professional artists and amateur pianists, and institutions through independent dealers primarily in the United States, Germany, Austria, Switzerland, the United Kingdom, France, and Italy. It operates six retail showrooms in the United States and five retail showrooms in Europe. The Band & Orchestral Instruments segment manufactures and sells piccolos, flutes, clarinets, oboes, bassoons, trumpets, French horns, tubas, and trombones, as well as intermediate and professional level woodwind and brass instruments under Bach, Selmer, Selmer Paris, C.G. Conn, Leblanc, King, Armstrong, Holton, Yanagisawa, Vito, Emerson, Avanti, Noblet, Artley, and Benge brands; distributes saxophones and clarinets; manufactures and distributes acoustical and tuned percussion instruments, including outfit drums, marching drums, concert drums, marimbas, xylophones, vibraphones, orchestra bells, and chimes; distributes violins, violas, cellos, and basses under Glaesel, Scherl & Roth, and William Lewis & Son brands; and manufactures mouthpieces and distributes accessories, such as music stands, batons, mallets, straps, mutes, reeds, pads, chin rests, strings, bows, cases, and instrument care products. This segment sells its products to students, amateur and professional musicians, and institutions through independent musical instrument dealers and distributors primarily in the United States, Europe, Latin America, and Asia. The company, formerly known as Selmer Industries, Inc., was founded in 1993 and is based in Waltham, Massachusetts.

Advisors' Opinion:

• [By Eric Volkman]

  Steinway Musical Instruments (NYSE: LVB  ) has ceased to be the owner of its iconic Steinway Hall in New York City. The company formally closed a deal to sell the building to a partnership headed by real estate concern JDS Development Group. Steinway received $46.3 million in the acquisition, and will recognize a taxable gain of roughly $22 million.

10 Best Life Sciences Stocks To Invest In Right Now: Microvision Inc.(MVIS)

MicroVision, Inc. engages in the development of miniature laser display and imaging engines based upon its proprietary PicoP display engine technology. Its technology uses two dimensional micro-electrical mechanical systems, lasers, optics, and electronics to create a video or still image from a small form factor device. The company offers Pico projector displays intended to be used for users of mobile consumer devices, such as smartphones, media players, tablet PCs, and other consumer electronics products. Its products also comprise automotive head-up displays that project high-resolution images onto the windshield of an automobile providing the driver with information consisting of GPS mapping images, audio controls, and other automobile instrumentation information related to the car's operation. In addition, the company offers near-eye wearable display platform to provide personal viewing of information from a mobile device through a wired or wireless connection. Furthe r, it offers ROV hand held bar code scanners, and bar code scanner enabled enterprise solutions through distributors and original equipment manufacturers, as well as directly to end users through its online store. The company serves customers operating in the consumer, defense, industrial, and medical markets. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

Advisors' Opinion:

• [By James E. Brumley]

  Did you miss the first big runup from Microvision, Inc. (NASDAQ:MVIS) a couple of weeks ago? If you were regretting it then, it may have all worked out for the best. Though MVIS jumped from a close of $1.35 on the 19th to a peak of $3.38 on the 21st, it was also on the 21st that the weight of that big gain started to bear down. By the 25th, Microvision shares hit a low of $2.01, basically cutting in half the 150% gain that has been made in just a couple of days.

• [By Charley Blaine]

  Shares of MicroVision Inc. (NASDAQ: MVIS) were jumping for a second day in a row Friday on the heels of Sony Inc.’s (NYSE: SNE) introduction of a new handheld projector that uses Microvision’s technology.

• [By Bryan Murphy]

  If the cash you have available is money you absolutely need to invest safely and wisely because you need it (and its appreciation) to love on in retirement, then let me stop you right now - the rest of what you're about to read probably isn't for you. On the other hand, if you and your qualified financial adviser agree you've got some money you can gamble with [i.e. if you lose it all, it won't matter], then may I direct your attention to Microvision, Inc. (NASDAQ:MVIS)? Long story made short, MVIS has dropped hints of a brewing rebound.

10 Best Life Sciences Stocks To Invest In Right Now: Solarwinds Inc.(SWI)

SolarWinds, Inc. designs, develops, markets, sells, and supports enterprise information technology (IT) infrastructure management software for IT professionals in various organizations in the United States and internationally. The company offers enterprise-class IT management products, including Network Performance Monitor, a server-based fault and performance management platform to minimize network downtime; Network Performance Monitor modules, a series of add-ons; network configuration manager to automate the processes of network device discovery, network inventory management, and network change management; user device tracker, a server-based switch port management tool; scalability engines to increase the scale of a number of the products; and enterprise operations console to provide web-based views of various instances of Network Performance Monitor modules and Application Performance Monitor. Its enterprise-class network and IT management products also comprise Applic ation Performance Monitor, a server-based availability and performance management system for applications and server infrastructure; patch manager to automate the process of deploying, managing, and reporting on patches and configuration settings; and synthetic end user monitor to capture the user steps of any web application and monitor the end-user experience; storage manager that combines reporting, monitoring, and notification on the performance of storage resources; backup profiler to provide a consolidated view of the status of backup operations; virtualization manager to manage various aspects of virtual server infrastructure; and log and event manager to automate the collection and interpretation of logs. In addition, the company provides free tools, such as desktop, laptop, server-based, or internet-based applications; and tools and toolsets for specific solutions of routine and complicated tasks. The company was founded in 1999 and is headquartered in Austin, Texas .

Advisors' Opinion:

• [By Hilary Kramer]

  Next Page

  Tech Stocks That’ll Survive: SolarWinds (SWI)

  SolarWinds (SWI), contrary to what you might think from its name, is not a solar company. It is a software company with a presence in both virtualization and security, and offers solid profit potential thanks to dedicated customers and a growth rate that is already outpacing the overall industry.

• [By Travis Hoium]

  What: Shares of SolarWinds (NYSE: SWI  ) dropped 14% today as investors reacted to the company's acquisition plans.

  So what: Yesterday, the company announced it will buy N-able, a cloud-based IT infrastructure company, for $120 million. This is expected to reduce 2013 earnings and there's no guarantee the acquisition will pay off, so investors sold off shares today. �

Hot Promising Stocks To Own Right Now

Hot Promising Stocks To Own Right Now: Controladora Vuela Compania de Aviacion SAB de CV (VLRS)

Controladora Vuela Compania de Aviacion SAB de CV (Volaris Aviation Holding Company) is a Mexico-based company principally engaged in the airline passenger transportation industry. The Company is a law-cost carrier airline. Controladora Vuela Compania de Aviacion SAB de CV offers direct, point-to-point flights. The Company serves through secondary, lower cost airports and provides a single class of service. The Company utilizes such aircraft as the Airbus A319 and A320 families, among others. The Company has such subsidiaries as Comercializadora Volaris SA de CV, Servicios Corporativos Volaris SA de CV, Concesionaria Vuela Compania de Aviacion SAPI de CV, Deutsche Bank Mexico SA Trust 1484, among others. Advisors' Opinion:

• [By John Udovich]

  When most American investors think of discount airline stocks, they probably think of relatively large capped Southwest Airlines Co (NYSE: LUV)or sort of small capJetBlue Airways Corporation (NASDAQ: JBLU) rather thansmall cap Controladora Vuela Co Avcn SA CV (NYSE: VLRS) which owns Volaris a discount airline serving theMexican market. However, any investor who has read Benjamin Grahams Intelligent Investor might want to remember his sage advice about avoiding airline stocks mainly because airlines were such a new and unproven sector that had yet to make money. But could Controladora Vuela Co Avcn SA CV actually be an airline stock worth owning?

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-promising-stocks-to-own-right-now-2.html

5 Best Recreation Stocks To Invest In Right Now

5 Best Recreation Stocks To Invest In Right Now: Manchester United PLC (MANU)

Manchester United plc, formerly Manchester United Ltd., incorporated on April 30, 2012, is engaged in the operations of professional sports team. It provides manchester united a platform to generate revenue from multiple sources, including sponsorship, merchandising, product licensing, new media & mobile, broadcasting and matchday. The Company had three principal sectors: Commercial, Broadcasting and Matchday.

Commercial

Within the Commercial revenue sector, the Company had three revenue streams which include sponsorship revenue; retail, merchandising, apparel and product licensing revenue; and new media and mobile revenue. Retail, Merchandising, Apparel and Product Licensing, it markets and sells sports apparel, training and leisure wear and other clothing featuring the Manchester United brand on a global basis. In addition, it also sells other licensed products, from coffee mugs to bed spreads, featuring the Manchester United brand and trademar ks. These products are distributed through Manchester United branded retail centers and e-commerce platforms, as well as its partners' wholesale distribution channels.

The Company retails, merchandizes, apparel & product licensing business is managed by Nike, who pays it a minimum guaranteed amount and a share of the business' cumulative profits. It has formed mobile telecom partnerships in 44 countries. In addition, it markets content directly to its followers through its Website, www.manutd.com, and associated mobile properties.

Broadcasting

The Company generates revenue from distribution and broadcasting of live football content. Broadcasting revenue is derived from the global television rights relating to the Premier League, Champions League and other competitions. In addition, its global television channel, MUTV, delivers Manchester United programming to 54 countr! ies around the world. Broadcasting includes all revenue covering do mestic and international television and radio rights. Broadc! asting revenue including, in some cases, prize money received by it in respect of the various competitions.

Matchday

The Company generates revenue during the matchday from the Old Trafford, a sports venue.

Other Matchday revenue includes matchday catering, event parking, program sales as well as membership and travel, Manchester United Museum revenue and a share of the ticket revenue from away matches in domestic cup competitions. Matchday revenue also includes revenue from other events hosted at Old Trafford, including other sporting events (including football matches as part of the London 2012 Olympic Games and the annual Rugby Super League Grand Final), music concerts and entertainment events.

Advisors' Opinion:

• [By Trista Kelley]

  Science in Sport was created by cycling enthusiast Tim Lawson in a kitchen in 1992 and was bought by Provexis two years ago. About 60 percent of sales come from cyclists, though the brand has been raising its profile among other athletes with help from the London Olympics last year and from Wimbledon champion and Go gel user Andy Murray. SiS has also widened its appeal to soccer fans, supplying products to Manchester United Plc (MANU) players, Moon said.

• [By Rich Smith]

  This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense and which ones investors should act on. Today, our headlines feature upgrades for mini-industrialist Stratasys (NASDAQ: SSYS  ) and for remote computer access specialist LogMeIn (NASDAQ: LOGM  ) but a downgrade for publicly traded soccer club Manchester United (NYSE: MANU  ) . Let's take them one at a time, beginning with...

• [By WWW.GURUFOCUS.COM]

  Manchester United plc (MANU) is an English Premier L! eague pro! fessional sports team. The business has three principal segments: Commercial, Broadcasting and Matchday. Soccer is the most popular sport in the world and is now the second most popular sport among the 12-24 age group in the U.S. Manchester United is a global brand, with a proven history of success, having won 12 of the last 20 Premier League Titles. It is the most popular soccer team in the world, with over 600 million fans! The company is positioned to benefit from greater broadcast fees and higher sponsorship and merchandising revenue, generating substantially more cash flow. We think of Manchester United as the most popular television program in the world that has not yet monetized the value of its brand. (Ashim Mehra)

• [By CRWE]

  Manchester United plc (NYSE:MANU), one of the most popular and successful sports teams in the world, playing one of the most popular spectator sports on Earth, reported that it has rescheduled its fourth quarter and fiscal 2012 earnings conference call and live webcast.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/5-best-recreation-stocks-to-invest-in-right-now.html

10 Best Information Technology Stocks To Invest In Right Now

10 Best Information Technology Stocks To Invest In Right Now: Cadiz Inc.(CDZI)

Cadiz Inc. engages in the acquisition and development of land and water resources in the United States. It focuses on water resource, agricultural, and solar energy development operations. The company owns approximately 35,000 acres of land in the Cadiz and Fenner valleys of eastern San Bernardino County; and approximately 10,800 additional acres in the eastern Mojave Desert, including the Piute and Danby Lake properties. It also engages in the cultivation of lemons, grapes/raisins, and spring and fall plantings of vegetables. Cadiz Inc. was founded in 1983 and is based in Los Angeles, California.

Advisors' Opinion:

• [By James E. Brumley]

  At first glance, today's action from Cadiz Inc. (NASDAQ:CDZI) just looks like a little bad luck, or a well-deserved break following a very strong, uninterrupted runup. The longer one looks at CDZI, however, the more red flags start to wave... red flags suggesting a substantial pullback may have just begun.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/10-best-information-technology-stocks-to-invest-in-right-now-2.html

Top 5 Asian Stocks To Buy For 2015

Top 5 Asian Stocks To Buy For 2015: NXP Semiconductors N.V.(NXPI)

NXP Semiconductors N.V., through its subsidiary, NXP B.V., provides mixed signal solutions and standard products worldwide. The company provides amplifiers, audio/radio products, bipolar transistors, data converters, diodes, identification and security products, interface and connectivity products, logic devices, media processors, microcontrollers, MOSFETs, power management integrated circuits (IC), radio frequency devices, sensors, thyristors, television and set-top-box front ends, and logic driver and controller ICs, as well as ESD, EMI, and signal conditioning products. Its products are used in automotive, identification, wireless infrastructure, lighting, mobile, consumer, computing, and industrial applications. NXP Semiconductors N.V. markets its products directly and through distribution to various original equipment manufacturers, original design manufacturers, contract manufacturers, and distributors. The company was formerly known as KASLION Acquisition B.V and ch anged its name to NXP Semiconductors NV in May 2010. NXP Semiconductors N.V. was founded in 2006 and is headquartered in Eindhoven, the Netherlands.

Advisors' Opinion:

• [By Paul Ausick]

  NXP Semiconductors N.V. (NASDAQ: NXPI) not only makes parts for the iPhone, but will benefit from the build-out of China Mobile’s base station infrastructure. The wireless carrier plans to support more than 500,000 base stations by the end of 2014, up from around 200,000 today. The stock closed on Friday at $43.52, in a 52-week range of $24.66 to $44.75. Sterne Agee’s price target on the stock is $50.00, yielding an upside potential of 14.9%. The consensus estimate for the 2014 fiscal year is $4.07, and the forward multiple at that level is 10.69. Shares were up 3.3% in premarket trading this morning.

• [By MONEYMORNING.COM]

  And here you'll find Strategic Tech Investor favorites like fabless chip firm NXP! Semiconductors NV (Nasdaq: NXPI) and Russian Internet giant Yandex NV (Nasdaq: YNDX).

• [By MONEYMORNING.COM]

  176.5% on NXP Semiconductors NV (Nasdaq: NXPI), which we'd recommended in May 2012 at $23.40 a share, and then re-recommended a number of times thereafter. Shares of the near-field-communications (NFC) chipmaker hit a new lifetime high of $64.69 this month and are still 168% higher than when we first told you about them.

• [By Ashraf Eassa]

  No. 1: NXP Semiconductor
  According to a leak from Sonny Dickson, the next-generation iPhone will have a built-in near field communication chip from NXP Semiconductors (NASDAQ: NXPI  ) . NFC lets devices connect wirelessly by putting them close together.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-asian-stocks-to-buy-for-2015-2.html

Top Medical Stocks To Buy For 2014

Are health insurers corporate equivalents of the super-villains in the "Despicable Me" movies? Many Americans might think so. Stories abound of examples where individuals felt they weren't treated as well as they should have been by their health insurance company.�

But, like the cartoon character Gru in the animated movies, health insurers aren't as bad as they might seem at first glance. This is certainly borne out in the latest results from the National Health Insurer Report Card published by the American Medical Association, or AMA. Here are five myths about health insurers that don't hold water, according to the AMA's findings.

Myth No. 1: Health insurers require prior authorizations a lot.
Prior authorizations are a way that insurers control costs by limiting payment for a service unless it's approved in advance. You might think that the practice would be used extensively to keep expenses down and profits up. But prior authorizations are used in only a small fraction of cases.

Best Life Sciences Companies To Own For 2015: Oramed Pharmaceuticals Inc (ORMP)

Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides. The Company owns oral dosage form drug portfolio, it is, on an on-going basis, considering in-licensing and other means of obtaining additional technologies to complement and/or expand the product portfolio. The Company�� products include ORMD-0801 - Oral Insulin Capsule and ORMD-0901 - Oral Exenatide.

The Company focuses to conduct research and development on the technology covered by the patent application Methods and Composition for Oral Administration of Proteins. Through its research and development efforts, it focuses to develop an oral dosage form that will withstand the chemical environment of the stomach and intestines and will be effective in delivering active insulin for the treatment of diabetes. It intends to conduct the clinical trials to file an Investigational New Drug (IND), application with the United States Food and Drug Administration (FDA). It also focuses to conduct research and development by deploying its drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop other pharmaceutical products.

Advisors' Opinion:

• [By Lisa Levin]

  Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 21.26% to $14.20. The volume of Oramed Pharmaceuticals shares traded was 621% higher than normal. Oramed shares have jumped 187.01% over the past 52 weeks, while the S&P 500 index has gained 28.75% in the same period.

• [By Lisa Levin]

  Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 15.68% to $17.85. The volume of Oramed Pharmaceuticals shares traded was 971% higher than normal. Oramed received patent allowance in Israel, Australia for platform technology in oral delivery of proteins.

• [By Ben Levisohn]

  Oramed Pharmaceuticals (ORMP) has dropped 19% to $12.11 after the company said it would sell nearly 1.6 million shares of stock for $10 a share.

  BP plc (BP) has fallen 0.7% to $47.24 after a U.S. judge refused its request to revise the way damages from the Deepwater Horizon oil spill are calculated.

Top Medical Stocks To Buy For 2014: NanoViricides Inc (NNVC)

NanoViricides, Inc., incorporated on April 1, 2005, is a development-stage company. The Company is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company has several drugs in various stages of early development. The Company�� drugs are based on several patents, patent applications, provisional patent applications, and other property held by TheraCour Pharma, Inc. (TheraCou), to which the Company has exclusive licenses in perpetuity for the treatment of human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. As of June 30, 2012, the Company had six drug development programs: Oral FluCideTM, against all Influenzas; a Piggy-back version of Flucide for hospitalized patients; nanoviricide eye drops against adenoviral EKC and herpes keratitis; HIVCide - I against HIV/AIDS; HerpeCide - I skin cream formulation for herpes cold sores and genital warts, and DengueCide, a broad spectrum nanoviricide designed to attack all types of dengue viruses and expected to be effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome (DSS). As of June 30, 2012, it had engaged in organizational activities, sourcing compounds and materials, developing novel compounds and nanomaterials, and experimentation with studies on cell cultures and animals. In September 2011, NanoViricides Inc's Inno-Haven LLC acquired a light industrial building.

The Company's product development programs are divided into three sectors: commercially important diseases, neglected tropical diseases (NTD��) and biosecurity/biodefense, and advanced technologies. The Company has collaborations with KARD Scientific, Inc., MA. and Southern Research Institute, AL for influenza viruse! s; National (Central) Institute of Hygiene and Epidemiology (NIHE) (Vietnam), for H5N1 avian flu; The Long Island Jewish Medical System, Feinstein Institute of Medical Research (LIJMS), NY and TheVac, LLC. for viral diseases of the eye (adenoviruses, herpesviruses - epidemic kerato-conjunctivitis (EKC), Herpes Keratitis); TheVac, LLC and Northeastern Ohio Medical University (NEOMED) for herpes virus infections; University of California at Berkeley for dengue hemorrhagic fever viruses; Center for Disease Control and Prevention (CDC) and National (Central) Institute of Hygiene and Epidemiology for rabies virus. The Company has developed lead drug candidates against a number of viral diseases.

The Company had consolidated all of its influenza drug programs into a single pan-influenza FluCide program. It is developing a single drug for all influenzas, whether pandemic, epidemic, seasonal, novel, emerging, human, swine, or avian. It is developing a nanoviricide against adenoviral EKC. The nanoviricide eye drug candidate is formulated as simple eye drops. It is developing an anti-HSV nanoviricide skin cream formulation for direct application to the lesions. It has designed the anti-HIV nanoviricides using rational drug design principles. The ligands it has designed in the case of HIV-1 are thought to be broadly neutralizing. In-silico modeling indicates that its ligands dock to the conserved CD4 binding site of gp120 of HIV-1. The Company is working on developing anti-Dengue therapeutics. Dengue is an important NTD. Its RabiCide program has resulted in candidates that have enabled survival of 20% to 30% of infected animals after disease has set in, using a particular animal model.

The Company competes with Roche, Glaxo SmithKline, BioCryst Pharmaceuticals, Inc., Gilead, Bristol-Myers Squibb Company (BMS), Roche, Boehringer Ingelheim, Merck & Co., Inc. (Merck), Valeant, Schering, Pharmassett, Vertex, Intermune, Achillion and Novartis.

Advisors' Opinion:

• [By Roberto Pedone]

  
  

  One under-$10 nano-biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Nanoviricides (NNVC), which engages in the discovery, development and commercialization of anti-viral therapeutics primarily in the U.S. This stock has been ripping to the upside so far in 2013, with share up big by 198%.

  If you take a look at the chart for Nanoviricides, you'll notice that this stock has recently formed a double bottom chart pattern at $4.55 to $4.52 a share. Following that bottom, shares of NNVC have now started to uptrend and move within range of triggering a big breakout trade. That trade will hit if NNVC manages to take out the upper-end of its recent sideways trading chart pattern, which has seen NNVC trend between $4.55 and $5.74 a share.

  Traders should now look for long-biased trades in NNVC if it manages to break out above some near-term overhead resistance levels at Friday's high of $4.94 a share to its 50-day moving average of $5.28 a share, and then once it takes out some more key overhead resistance levels at $5.72 to $5.74 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 234,994 shares. If that breakout triggers soon, then NNVC will set up to re-test or possibly take out its next major overhead resistance levels at $6.50 to its 52-week high at $7.59 a share.

  Traders can look to buy NNVC off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.55 to $4.52 a share. One can also buy NNVC off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Medical Stocks To Buy For 2014: Furiex Pharmaceuticals Inc (FURX)

Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company�� product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V.

Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI) designed to be taken only when needed one to three hours before sexual intercourse is anticipated rather than every day. Nesina (alogliptin) is a drug for the oral treatment of type 2 diabetes (T2D). Alogliptin is a DPP-4 inhibitor that slows the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).

Fluoroquinolone drug candidate is a Phase II-ready novel fluoroquinolone antibiotic that is being developed by the Company for the treatment of complicated skin and skin structure infections, such as abscesses that occur deep in the skin layers and respiratory infections. This antibiotic has a spectrum of activity and is able to treat methicillin-resistant staphylococcus aureus (MRSA) infections. The Company is developing both oral and intravenous (IV) formulations. The Company is developing Mu Delta for treatment of diarrheal predominant irritable bowel syndrome (d-IBS). The Company is conducting a Phase II study on an oral formulation of Mu Delta.

The Company is developing PPD 10558 for the treatment of dyslipidemia. PPD 10558 has shown muscle safety in preclinical studies by minimizing the delivery of the drug to the muscle. The Company has filed an inve! stigational new drug (IND) application with the United States Food and Drug Association and completed five clinical studies.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Top Headline
  Forest Laboratories (NYSE: FRX) announced its plans to buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion. Forest will pay around $95 per share, or around $1.1 billion in cash. Forest Labs will also pay up to $30 per share, or around $360 million in a contingent value right. The deal is projected to close in the second or third quarter of 2014.

• [By Lisa Levin]

  Furiex Pharmaceuticals (NASDAQ: FURX) shares moved up 28.41% to $102.92. The volume of Furiex Pharmaceuticals shares traded was 2285% higher than normal. Forest Labs (NYSE: FRX) announced its plans to buy Furiex Pharma for up to $1.46 billion.

Top Medical Stocks To Buy For 2014: Galena Biopharma Inc (GALE)

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).

The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.

In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.

The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.

The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.

Advisors' Opinion:

• [By James E. Brumley]

  The last two weeks have been absolutely fantastic ones for Galena Biopharma Inc. (NASDAQ:GALE). Shares have soared from $2.37 to the current price of $3.32 - a 40% pop - rewarding investors who had been patiently waiting through late October for the runup to take hold. Congratulations if that's you. But, if that was you, then now might be a great time to take the money and run with the trade, as GALE looks poised to make a sizeable pullback. More on that in a moment.

• [By Sean Williams]

  The waiting game
  The tables are clearly stacked against small biotech companies developing cancer drugs. History has shown that few (if any) have successfully had the Food and Drug Administration approve a late-stage cancer drug. While mid-stage trials of Galena Biopharma's (NASDAQ: GALE  ) HER2-targeting breast cancer vaccine have been promising thus far, the chances of an approval seem a long way off.

• [By Paul Ausick]

  Stocks on the move: Galena Biopharma Inc. (NASDAQ: GALE) is down 15.4% at $1.93 after pricing a secondary offering of 17.5 million units at $2.00. Safeway Inc. (NYSE: SWY) is up 6.1% at $28.21, after an analyst�� upgrade which sent shares to a new 52-week high of $28.88 earlier. Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) is down 18.2% at $4.08.

• [By Michael Douglass and David Williamson]

  Galena Biopharma� (NASDAQ: GALE  ) announced this morning that it has licensed the rights to sell Zuplenz for $5 million in stock and cash, in addition to royalties, milestones, and an upfront payment.

10 Best Consumer Service Stocks To Invest In 2015

10 Best Consumer Service Stocks To Invest In 2015: Starbucks Corporation(SBUX)

Starbucks Corporation purchases and roasts whole bean coffees. It operates approximately 16,858 stores, including 8,833 company-operated stores and 8,025 licensed stores. The company offers approximately 30 blends and single-origin premium arabica coffees. It also provides handcrafted beverages, such as fresh-brewed coffee, hot and iced espresso beverages, coffee and non-coffee blended beverages, Vivanno smoothies, and Tazo teas; and merchandise products, including home espresso machines, coffee brewers and grinders, coffee mugs and accessories, packaged goods, music, books, and gift items. In addition, it offers fresh food items, which comprise baked pastries, sandwiches, salads, oatmeal, yogurt parfaits, and fruit cups. Further, it also provides VIA ready brew coffee, bottled frappuccino beverages, discoveries chilled cup coffee, doubleshot espresso drinks, iced coffee, whole bean coffee, and ice creams. The company?s brand portfolio includes Tazo tea, Ethos water, Seatt le?s Best Coffee, and Torrefazione Italia Coffee. Starbucks Corporation sells its products in approximately 50 countries worldwide. Starbucks Corporation was founded in 1971 and is based in Seattle, Washington.

Advisors' Opinion:

• [By Rick Munarriz]

  Green Mountain has more to lose than it could gain in taking SodaStream head on here, so why isn't anyone pointing the finger at Starbucks (NASDAQ: SBUX  ) ?

• [By Bob Ciura]

  Just three years ago, Dunkin' Brands (NASDAQ: DNKN  ) was the next great growth stock. The market fell in love with the doughnut maker's growth story after the company's 2011 initial public offering. At that time, investors sent Dunkin' shares soaring more than 50% on their first day of trading. The rally continued, and Dunkin' Brands soon turned into a high-multiple growth stock akin toStarbucks (NASDAQ: SBUX  ) .

source fro! m Top Penny Stocks For 2015:http://www.seekpennystocks.com/10-best-consumer-service-stocks-to-invest-in-2015.html

Hot Consumer Service Companies To Buy Right Now

Hot Consumer Service Companies To Buy Right Now: Costamare Inc (CMRE)

Costamare Inc. (Costamare), incorporated on April 21, 2008, is an international owner of containerships, chartering the Companys vessels to liner companies. As of February 22, 2013, it had a fleet of 57 containerships aggregating approximately 332,000 twenty feet equivalent unit (TEU). During the year ended December 31, 2012, its fleet consisted of 47 vessels in the water, aggregating approximately 242,000 TEU. The Companys containerships operate primarily under multi-year time charters.

As of February 22, 2013, the average (weighted by TEU capacity) remaining time-charter duration for its fleet of 57 containerships was 5.1 years. During the year ended December 31, 2012, the Companys vessels were managed by at least one of Costamare Shipping, CIEL and Shanghai Costamare. The Companys customers include international liner companies, including A.P. Moller-Maersk, COSCO, Evergreen Marine, Hapag Lloyd, HMM, MSC and ZIM.

Advisors' Opinion:

• [By Seth Jayson]

  Costamare (NYSE: CMRE  ) reported earnings on July 24. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended June 30 (Q2), Costamare missed estimates on revenues and beat expectations on earnings per share.

• [By Rich Duprey]

  Containership owner and providerCostamare (NYSE: CMRE  ) announced yesterday its second-quarter dividend of $0.27 per share, the same rate it's paid since late 2011.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-consumer-service-companies-to-buy-right-now-2.html

Hot Recreation Companies To Invest In Right Now

It appears that scam artists are now targeting medical marijuana and legalized marijuana schemes to part you from your money. As the business opportunities are rising around the new and controversial field of legalized marijuana, so are the number of scams. The Financial Industry Regulatory Authority, known as FINRA in the financial industry, has issued a new investor alert targeting Marijuana Stock Scams. FINRA is warning investors about potential related scams and we are surprised that the same warning is not being sent out by the U.S. Securities and Exchange Commission.

The FINA data confirmed that medical marijuana is legal in almost 20 states, and is now recreationally legal in two states, garnering much attention to the cannabis industry. FINRA warns:

Like many investment scams, pitches for marijuana stocks may arrive in a variety of ways — from faxes to email or text message invitations, to webinars, infomercials, tweets or blog posts. … The con artists behind marijuana stock scams may try to entice investors with optimistic and potentially false and misleading information that in turn creates unwarranted demand for shares of small, thinly traded companies that often have little or no history of financial success. The scammers behind these “pump and dump” scams can then sell off their shares, leaving investors with worthless stock.

Top 5 Regional Bank Companies To Watch In Right Now: Drew Industries Inc (DW)

Drew Industries Incorporated, incorporated on March 20, 1984, is a supplier of components for recreational vehicle (RVs) and manufactured housing. The Company operates in two segments: the RV products segment (RV Segment), and the manufactured housing products segment (MH Segment). The Company�� operations are conducted through its wholly owned subsidiaries, Lippert Components, Inc. and its subsidiaries (Lippert) and Kinro, Inc. and its subsidiaries (Kinro), each of which has operations in both the RV Segment and the MH Segment. During the year ended December 31, 2012, the RV Segment accounted for 87% of net sales and the MH segment accounted for 13% of net sales. On February 21, 2012, the Company acquired the business and certain assets of the United States RV entry door operation of Euramax International, Inc. In February 2014, the Company's wholly-owned subsidiary, Lippert Components, Inc has acquired Innovative Design Solutions, Inc. (IDS).

RV Segment

The Company through its wholly owned subsidiaries manufactures and markets a variety of products used in the production of RVs, including steel chassis for towable RVs, axles and suspension solutions for towable RVs, slide-out mechanisms and solutions, thermoformed bath, kitchen and other products, manual, electric and hydraulic stabilizer and lifting systems, aluminum windows and screens, chassis components, furniture and mattresses, entry, baggage, patio and ramp doors, entry steps, awnings, and other accessories. The Company also supplies certain of these products to the RV aftermarket, and to adjacent industries, including manufacturers of truck caps, buses and trailers used to haul boats, livestock, equipment and other cargo. Operations of the Company's RV Segment consist primarily of fabricating, welding, painting and assembling components into finished products. The Company's RV Segment operations are conducted at 23 manufacturing and warehouse facilities throughout the United States, located in proximity to the cus! tomers they serve. Of these facilities, six also conduct operations in the Company's MH Segment. It markets extruded aluminum parts to manufacturers in other industries. The Company's RV Segment products are sold primarily to manufacturers of RVs such as Thor Industries Forest River (a subsidiary of Berkshire Hathaway, and other original equipment manufacturers (OEMs), and to distributors of aftermarket products.

MH Segment

The Company through its wholly owned subsidiaries manufactures and markets a variety of products used in the production of manufactured homes and to modular housing and mobile office units, including vinyl and aluminum windows and screens, steel chassis, steel chassis parts, axles, thermoformed bath and kitchen products, steel and fiberglass entry doors, and aluminum and vinyl patio doors. The Company also supplies windows, doors, and thermoformed bath products as replacement parts to the manufactured housing aftermarket, and to adjacent industries. MH Segment customers manufacture both manufactured homes and modular homes, and certain of the products manufactured by the Company are suitable for both types of homes. Operations of the Company's MH Segment consist primarily of fabricating, welding, thermoforming, painting and assembling components into finished products. The Company's MH Segment operations are conducted at 13 manufacturing and warehouse facilities throughout the United States, located in proximity to the customers they serve. Of these facilities, six also conduct operations in the Company's RV Segment. The Company's manufactured housing products are sold primarily to producers of manufactured homes such as Clayton Homes, Cavco Industries, Inc., Champion Home Builders, Inc., Skyline Corporation, and other OEMs, and to distributors of aftermarket products.

The Company competes with Kober Corporation and Dexter Axle Company.

Advisors' Opinion:

• [By John Udovich]

  The CEO of recreation vehicle (RV) stock Winnebago Industries, Inc (NYSE: WGO) recently appeared on CNBC to say that the economy is improving for RV makers, meaning its time to take a closer look at the stock plus take a look at the performance of other small cap RV stocks like Drew Industries, Inc (NYSE: DW), Skyline Corporation (NYSEMKT: SKY) and Thor Industries, Inc (NYSE: THO).

• [By Grace L. Williams]

  Shares of Winnebago have gained 4.4% to $28.47 today at 3pm. Thor Industries (THO), which also makes recreational vehicles, has ticked up 0.1% to $57.56, Drew Industries (DW) has risen 0.3% to $48.74, Arctic Cat (ACAT) has advanced 1% to $59.87 and Polaris Industries (PII) has fallen 0.3% to $132.08.

Hot Recreation Companies To Invest In Right Now: Dale Jarrett Racing Adventure Inc (DJRT)

Dale Jarrett Racing Adventure, Inc., incorporated on November 24, 1998, offers entertainment based oval driving schools and events. The Company owns several National Association for Stock Car Auto Racing (NASCAR) type racecars. These classes are conducted at various racetracks throughout the country. As of December 31, 2011, the Company owned 15 racecars, and had purchased six additional racecars for its Las Vegas hub. These racecars are classified as stock cars and are equipped for oval or round tracks only.

The Company offers five types of ride or drive programs for individuals and corporations. The Qualifier is a three lap ride with a professional driver, which lasts about five minutes, depending on the length of the track. The Season Opener is a half day training class culminating in the student driving 10 laps. The Rookie Adventure and Happy Hour are also half day driving classes with the students driving 20 or 30 laps, respectively. The Advanced Stock Car Adventure is a full day 60 lap class. The main purpose of each event is the thrill of actually driving the race car. It owns a Miller Semi Tractor Trailer to haul the cars from track to track. The Company also offers a range of add-on sale items, including compact disks (CDs) from its adventure cam located in the car, clothing, souvenirs and photography.

The Company competes with Richard Petty Driving Experience.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Alliance Creative Group Inc (OTCMKTS: ACGX), Dale Jarrett Racing Adventure Inc (OTCMKTS: DJRT), Inscor Inc (OTCMKTS: IOGA) and Solar Thin Films Inc (OTCMKTS: SLTZ) have all been getting some attention lately in various investment newsletters and it should come as no surprise that two out of four of these stocks have been the subject of paid promotions ��which tend to benefit traders. However, two out of four of these stocks also have pretty good financials for being small cap OTC stocks and that might make them attractive to investors with a long term time horizon. So which of these stocks might make traders some profits in the short term and investors some profits over the longer term? Here is a closer look to help you decide:

Hot Recreation Companies To Invest In Right Now: Marine Products Corp (MPX)

Marine Products Corporation (Marine Products), incorporated on August 31, 2000, designs, manufactures and sells recreational fiberglass powerboats in the sportboat, deckboat, cruiser, sport yacht and sport fishing markets. The Company sells its products to a network of 135 domestic and 69 international independent authorized dealers. The Company focuses to remain a manufacturer of recreational powerboats for sale to a range of consumers globally. The Company manufactures Chaparral sterndrive and inboard-powered pleasure boats including H2O Sport and Fish & Ski boats, SSi and SSX Sportboats, Sunesta Sportdecks and Xtreme Tow boats, Signature Cruisers, Premiere Sport Yachts and Robalo outboard sport fishing boats. The Company offers a range of products to the family recreational, cruiser and sport yacht markets through its Chaparral brand, and to the sport fishing market through its Robalo brand.

The Company's products include Chaparral - H2O Sport Series, which is a fiberglass multipurpose runabouts; Chaparral - SSi Wide tech, which is a fiberglass closed deck runabouts; Chaparral - SSX Sportdecks, which is a fiberglass bowrider crossover sportboats; Chaparral - Sunesta Xtreme Tow Boats, which is a fiberglass pleasure boats; Chaparral - Signature Cruisers, which is a fiberglass, accommodation-focused cruisers; Chaparral - Premiere Sport Yacht, which is a fiberglass sport yacht, and Robalo - Sport Fishing Boats, which is a sport fishing boats for freshwater lakes or saltwater use. Domestic sales are made through approximately 74 Chaparral dealers, 16 Robalo dealers and 45 dealers that sell both brands located in markets throughout the United States. Marine Products also has 69 international dealers.

The Company competes with Sea Hunt, Sea Fox, Grady-White, Boston Whaler, Everglades and Parker.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Marine Products (NYSE: MPX  ) , whose recent revenue and earnings are plotted below.

• [By Sean Williams]

  Sink or swim
  Sometimes the best short-sale opportunities are small, under-the-radar companies. One that I feel fits the bill perfectly is fiberglass boat maker Marine Products (NYSE: MPX  ) .

Hot Recreation Companies To Invest In Right Now: Nikon Corp (NINOY)

NIKON CORPORATION is a Japan-based company mainly engaged in the manufacture and sale of optical products. The Company is active in four business segments. The Precision Apparatus segment offers semiconductor exposure apparatus and liquid crystal (LC) exposure apparatus. The image segment provides digital cameras, film cameras and interchangeable lens. The Instruments segment offers microscopes, measuring machines and semiconductor inspection equipment. The Others segment provides glass materials, telescopes, glasses and survey airplanes.

As of August 19, 2009, the Company held a 92.17% stake in Metis NV. The Company has 65 subsidiaries and 10 associated companies in the country and overseas markets.

Advisors' Opinion:

• [By Dan Carroll]

  Unfortunately, the yen's impact on stocks has blurred the lines on investments. Look no further than down-on-its-luck camera maker Nikon (NASDAQOTH: NINOY  ) . Nikon's shares gained more than 8% over the past week due to the yen's weakness, as the company rakes in more than a quarter of its sales in Europe. Still, the stock's lost more than 43% year to date.

Hot Recreation Companies To Invest In Right Now: Callaway Golf Co (ELY)

Callaway Golf Company, incorporated on May 7, 1999, together with its subsidiaries, designs, manufactures and sells golf clubs (drivers, fairway woods, hybrids, irons, wedges and putters) and golf balls, and also sells golf accessories (such as golf bags, golf gloves, headwear, towels, umbrellas and travel gear) under the Callaway Golf and Odyssey brand names. The Company sells pre-owned golf products through its Website, www.callawaygolfpreowned.com. In addition, it sells Callaway Golf and Odyssey products direct to consumers online through its Websites shop.callawaygolf.com and www.odysseygolf.com. The Company also licenses its trademarks and service marks in exchange for a royalty fee to third parties for use on golf related accessories, including apparel, footwear, eyewear, rangefinders and practice aids. Its products are sold in the United States and in approximately 100 countries around the world.

The Company designs, manufactures and sells golf clubs and golf balls, and designs and sells golf accessories. The Company�� products are designed for golfers of all skill levels, both amateur and professional. The Company�� principal products include Drivers, Fairway Woods and Hybrids; Irons; Putters; Golf Balls, and Accessories, Softgoods and Other. Drivers, Fairway Woods and Hybrids product category includes sales of the Company�� drivers, fairway woods and hybrid products, which are sold under the Callaway Golf brand. Irons include sales of the Company�� irons and wedges, which are sold under the Callaway Golf brand. Putters include sales of the Company�� putters, which are sold under the Odyssey brand. Golf Balls includes sales of the Company�� golf balls, which are sold under the Callaway Golf and Strata brands. Accessories, Softgoods and Other includes sales of golf bags, golf gloves, golf footwear, rangefinders, golf apparel, packaged club sets, headwear, towels, umbrellas, eyewear and other accessories, as well as sales of pre-owned products through www.callawaygolfpre! owned.com. Additionally, this product category includes royalties from licensing of the Company�� trademarks and service marks on products such as golf apparel, golf footwear, rangefinders and practice aids.

The Company competes with TaylorMade, Ping, Acushnet, Puma, SRI Sports Limited, Mizuno, Bridgestone, and Nike.

Advisors' Opinion:

• [By Charley Blaine]

  Callaway Golf (NYSE: ELY) was also up, gaining 19.83 percent to $8.70 after the company reported a narrower third-quarter loss and lifted its 2013 forecast. DA Davidson upgraded the stock from Neutral to Buy and lifted its price target from $7.50 to $11.

• [By Rick Munarriz]

  3. Who's your caddy?
  Callaway Golf (NYSE: ELY  ) may have ushered in a new era in golfing with its oversized Big Bertha drivers, but these days, the golf gear maker keeps landing in the rough.

• [By Greg Pugh] Callaway Golf Company (NYSE: ELY) has forged a reputation as a leader in golf equipment innovation. However, the company started sliding in 2008 due to recession, while the brand image fell as well. US industry golf sales hit a floor and flattened just above $1.8 billion between 2009 and 2011, but have started to rebound in the last two years.

Hot Recreation Companies To Invest In Right Now: Medina International Holdings Inc (MIHI)

Medina International Holdings, Inc. (Medina), incorporated on June 23, 1998, manufactures products and services to assist emergency and defense organizations and personnel. The Company, through its two wholly owned subsidiaries, Harbor Guard Boats, Inc. (HGB) and Medina Marine, Inc. manufactures and sells recreational and commercial boats. The products are manufactured by HGB, which designs, manufactures, and markets hand-laid fiberglass and aluminum commercial boats ranging from 15 feet to 37 feet, which are utilized by fire, search and rescue, emergency, patrol, military and defense organizations. It manufactures commercial and recreational watercrafts.

As of April 30, 2012, HGB had nine models of commercial and recreational watercrafts. The Company�� products consist of commercial boats and recreational boats. As of April 30, 2012, Medina had seven commercial watercraft models, ranging from 15 feet to 37 feet in length. Its other watercraft includes 15 feet interceptor, which is used for rescue and fiber glass; 20-feet interceptor, which is used for fire rescue, rescue and fiber glass; 21 feet firecat, which is used for fire rescue, rescue and fiber glass; 24 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass; 26 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass; 30 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass, and 37 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass. As of April 30, 2012, the Company had two recreational watercraft models. Its watercraft products are made out of fiberglass and aluminum materials.

Advisors' Opinion:

• [By Peter Graham]

  Last Friday, small cap Digital Brand Media & Marketing Group Inc (OTCMKTS: DBMM) surged 22.22% while Blue Water Global Group Inc (OTCBB: BLUU) sank 18.42% and Medina International Holdings, Inc (OTCMKTS: MIHI) sank 50%. However, one of these small caps (Blue Water Global Group) appears to be reversing course in early morning trading today. So with it and the rest of these small cap stocks either sink or swim in trading this week? Here is a closer look to help you decide on an investing or trading strategy:

Football Teams with the Most Expensive Tickets

Tickets to a New York Giants 2013 home game are the most expensive in the NFL. The Chicago Bears and the New England Patriots have the second and third most expensive tickets.

While teams sell tickets directly, there is a thriving secondary market of tickets. Sources such as Stubhub, eBay and TicketNetwork.com SeatGeek, and many others provide a marketplace for fans to buy and sell tickets. The secondary market is more reflective of current demand.

Event ticket search engine SeatGeek provided 24/7 Wall St. with the current average secondary-market ticket prices for each team for the 2013 NFL season. Based on the data, the average 2013 game for several teams costs more than $200. Home games for the New York Giants cost $292.36

Click here to see the teams with the highest-price tickets

Most of the teams with the most expensive tickets have been successful in their recent seasons. Winning teams attract more people to the games and drive up ticket prices. Teams that make this list, including the New England Patriots, the Green Bay Packers and the Baltimore Ravens, are playoff contenders nearly every year. Of the 10 most recent Super Bowl champions, only one is not on this list of teams with the most expensive tickets.

According to SeatGeek representative Will Flaherty, the other teams to make this list, like the Seattle Seahawks and the Denver Broncos, have had recent surges in success and popularity, which have clearly driven up prices. The average secondary-market ticket for a Seahawks game in 2011 was $93.91. In 2012, the Seahawks displayed a dominant defense and were led by exciting rookie quarterback Russell Wilson. The average ticket price for the 2013 Seahawk season is $220.64, more than double the 2011 season ticket price.

The cost of secondary-market tickets is determined also by their original, primary market price. This, explained Flaherty, can be affected by the costs of living in the different cities. New York, Boston and Seattle, home to three of the most expensive teams, have among the highest costs of living in the country. In comparison, cities with the cheapest average football tickets — Cleveland, Jacksonville and St. Louis — have much lower costs of living.

Still, cost of living is not everything, Flaherty noted. Green Bay is not a particularly expensive market, but the waiting list for tickets is in the hundreds of thousands. "The Packers have insatiable demand, with a ticket waiting list of over 100,00 fans." This more than makes up for the less expensive market. At the same time, New York Jets games are among the cheapest tickets. This is despite the fact that Jets home games are held in MetLife stadium, the same stadium that the team with the most expensive ticket, the New York Giants, also calls home.

In order to identify the NFL teams with the most expensive tickets, event ticket search engine SeatGeek provided 24/7 Wall St. with the current average secondary-market ticket prices for each team for the 2013 NFL season. 24/7 Wall St. reviewed team record and attendance data from ESPN. We also reviewed city cost of living data as of the first quarter of 2013 from the Council for Community and Economic Research. All ticket prices listed are secondary-market ticket averages, provided by SeatGeek.

These are the NFL teams with the most expensive tickets.

Top 10 Promising Stocks To Watch For 2014

Popular Posts: 5 Biotech Stocks Promising Future Rewards3 Defense Stocks Set to Soar Into 2014The 3 Biggest Comeback Stories of 2013 Recent Posts: 2 Top Travel Stocks Trading Under $10 Coca-Cola Stock Has Lost Its Fizz Foot Locker Stock Looks to Bounce Higher View All Posts

Today, I want to focus on some of my favorite low-priced stocks. While the financial media may not always give $5 or $10 stocks their due, some of my best investments have been in overlooked low-priced stocks. And I know many new investors don’t like putting down $10,000 or $15,000 for only 100 shares of stock. If you count yourself among these ranks, I don’t blame you, and I have some good news to share with you.

Top 5 Services Stocks To Watch Right Now: Eastman Chemical Company (EMN)

Eastman Chemical Company, a chemical company, engages in the manufacture and sale of chemicals, plastics, and fibers in the United States and internationally. The company operates in four segments: Coatings, Adhesives, Specialty Polymers, and Inks (CASPI); Fibers; Performance Chemicals and Intermediates (PCI); and Specialty Plastics. The CASPI segment manufactures resins, specialty polymers, and solvents that are used in the production of paints and coatings, inks, adhesives, and other formulated products. The Fibers segment offers Estron acetate tow and Estrobond triacetin plasticizers used in cigarette filters; Estron natural and Chromspun solution-dyed acetate yarns for use in apparel, home furnishings, and industrial fabrics; and cellulose acetate flake and acetyl raw materials for acetate fiber producers. The PCI segment offers intermediates; performance chemicals; and complex organic molecules, such as diketene derivatives, specialty ketones, and specialty anhydrides for medical, pharmaceutical, fiber, and food and beverage ingredients, which are used in specialty market applications. This segment?s products are used in various markets and end uses, including agriculture, transportation, beverages, nutrition, pharmaceuticals, coatings, medical devices, toys, adhesives, household products, polymers, textiles, and consumer and industrial products, as well as used for health and wellness uses. The Specialty Plastics segment primarily offers engineering and specialty polymers, specialty film and sheet products, and packaging film and fiber products. This segment?s products include specialty copolyesters and cellulosic plastics, which are used in specialty packaging, in-store fixtures and displays, consumer and durable goods, medical goods, personal care and consumer packaging, photographic film, optical film, fibers/nonwovens, tapes/labels, and LCD?s. The company was founded in 1920 and is headquartered in Kingsport, Tennessee.

Advisors' Opinion:

• [By Seth Jayson]

  Eastman Chemical (NYSE: EMN  ) reported earnings on April 25. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Eastman Chemical missed estimates on revenues and beat expectations on earnings per share.

• [By Lauren Pollock]

  Eastman Chemical Co.'s(EMN) third-quarter earnings surged as the diversified chemical and materials producer reported sales growth as well as fewer charges related to its acquisition of Solutia Inc. last year. But it lowered its earnings estimate for the year on expectations it will continue to face challenges in its adhesives and plasticizers business, as well as higher raw-materials and energy costs. Shares dropped.

• [By John Divine]

  Quarterly results, or a lack thereof, were also the Achilles' heel of Eastman Chemical (NYSE: EMN  ) , which shed 5.1% today. Earnings actually came in above expectations, but sales numbers just didn't cut it, even though the company reported higher revenue in every single geographic region it reports in. Asia especially stood out as a segment of rapid growth, with those sales rocketing more than 50% higher. Although 48% sales growth in Europe, the Middle East, and Africa isn't too shabby, either, especially considering the macroeconomic worries and political instability surrounding those parts of the world.

• [By Michael A. Robinson]

  Today, Eastman Chemical Company (NYSE: EMN) ranks as an industry leader with a $12 billion market cap and whose stock is up 350% over the past five years, not counting the 1.5% dividend.

Top 10 Promising Stocks To Watch For 2014: Comcast Corporation(CMCSA)

Comcast Corporation, together with its subsidiaries, provides entertainment, information, and communications products and services in the United States and internationally. Its Cable Communications segment provides video, high-speed Internet, and phone services to residential and business customers. As of June 30, 2011, its cable systems served approximately 22.5 million video customers, 17.5 million high-speed Internet customers, and 9.1 million phone customers. The company?s Cable Networks segment operates cable entertainment networks, such as USA Network, Syfy, E!, Bravo, Oxygen, Style, G4, Chiller, Sleuth, and Universal HD; news and information networks, including CNBC, MSNBC, and CNBC World; cable sports networks comprising Golf Channel and VERSUS; regional sports and news networks; international entertainment, and news and information networks, such as CNBC Europe, CNBC Asia, and Universal Networks International portfolio of networks; cable television production oper ations; and digital media properties consisting primarily of brand-aligned Websites and other Websites, such as DailyCandy, Fandango, and iVillage. Its Broadcast Television segment operates the U.S. broadcast networks, NBC and Telemundo; 10 NBC and 15 Telemundo owned local television stations; broadcast television productions; and related digital media properties. The company?s Filmed Entertainment segment operates Universal Pictures, which produces, acquires, markets, and distributes filmed entertainment and stage plays worldwide in various media formats for theatrical, home entertainment, television, and other distribution platforms. Its Theme Parks segment operates Universal Studios Hollywood park and Wet ?n Wild water park, as well as licenses intellectual properties and provides services to third parties that own and operate Universal Studios Japan and Universal Studios Singapore. Comcast Corporation was founded in 1963 and is based in Philadelphia, Pennsylvania.

Advisors' Opinion:

• [By Wallace Witkowski]

  Plus, more than 120 companies on the S&P 500 report next week with notable releases from Apple Inc. (AAPL) and Biogen Idec Inc. (BIIB) �on Monday; Gilead Sciences Inc. (GILD) �and Allergan Inc. (AGN) �on Tuesday; Starbucks Corp. (SBUX) �, General Motors Co. (GM) , and Comcast Corp. (CMCSA) �on Wednesday; along with MasterCard Inc. (MA) �and ConocoPhillips (COP) �on Thursday.

Top 10 Promising Stocks To Watch For 2014: Colony Financial Inc (CLNY)

Colony Financial, Inc. is a real estate investment and finance company. The Company primarily acquires, originates and manages a diversified portfolio of real estate-related debt instruments. The Company focuses on acquiring, originating and managing commercial mortgage loans, which may be performing, sub-performing or non-performing loans (including loan-to-own strategies), and other commercial real estate-related debt investments. The Company is managed by Colony Financial Manager, LLC (the Manager) and an affiliate of the Company.

The Company also may acquire other real estate and real estate-related debt assets. The Company collectively refers to commercial mortgage loans, other commercial real estate-related debt investments, commercial mortgage-backed securities (CMBS), real estate owned (REO), properties and other real estate and real estate-related assets as its target assets.

Advisors' Opinion:

• [By Amanda Alix]

  For Wall Street types, single-family foreclosures can be bought cheaply and in bulk, then fixed up and rented. Companies like the Blackstone Group (NYSE: BX  ) and Colony Financial (NYSE: CLNY  ) have been very active in this market, with the former purchasing 16,000 homes just last year, and the latter ramping up its own portfolio to approximately 7,000. This new industry has also spawned fresh entrants from the REIT field, Silver Bay Realty (NYSE: SBY  ) and Altisource Residential, (NYSE: RESI  ) two trusts that were spun off earlier this year from parent companies Two Harbors Investment (NYSE: TWO  ) and Altisource Portfolio Solutions (NASDAQ: ASPS  ) , specifically to take advantage of the boom in the foreclosure-to-rental market.

• [By Amanda Alix]

  Is it risky to be putting so much money into an as-yet unproven business model? Some may think so, including investors. Noting the tumble in stock price that newbies like Silver Bay and American Residential have suffered recently, Colony Capital (NYSE: CLNY  ) chief Thomas Barrack postponed�the IPO of his new single-family rental company, Colony American Homes. Similarly, Public Storage (NYSE: PSA  ) has filed for an IPO, too, hoping to take its American Homes 4 Rent unit public -- at some unannounced, future date. In the meantime, American Homes can rely on its $500 million credit facility�with Wells Fargo, which may be bumped up to $1 billion if necessary.

• [By Amanda Alix]

  The investment-to-REIT model is alive and well
  Before the very end of last year, those involved in the single-family purchase and rental business were largely private equity groups�like the Blackstone Group (NYSE: BX  ) , Colony Financial (NYSE: CLNY  ) , and Oaktree Capital (NYSE: OAK  ) , which bought up distressed properties by the truckload.

Top 10 Promising Stocks To Watch For 2014: Rexahn Pharmaceuticals Inc (RNN)

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.

Archexin

Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.

Serdaxin

Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.

Zoraxel

Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.

The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.

Advisors' Opinion:

• [By James E. Brumley]

  With just a quick glance at a chart of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), it would be easy to conclude it's nothing but a volatile mess. When you take a step back and look at a long-term weekly chart of RNN, however, it starts to become clear that this small cap biopharma name is on the verge of a monster-sized breakout. First things first, however.

• [By James E. Brumley]

  If you were lucky enough to step into Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) when your truly suggested it was a budding buy back on December 23rd, then congratulations - you're now up a little more than 60% (assuming you bought into RNN after the break above a key resistance line on the 27th). Now get out. Instead, use your profits from the Rexahn to take on a stake in GTx, Inc. (NASDAQ:GTXI). No, GTXI may not look like much at first, but when you take a step back and look at a chart of GTx, Inc. through a longer-term lens, the upside potential becomes clear.

• [By John Udovich]

  So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:

• [By James E. Brumley]

  At first glance, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) doesn't look like anything particularly trade-worthy. The stock's now where it was in late October, and where it was in late September, and even where it was in late June. In other words, though RNN has been much higher and much lower than its current price of $0.46 over the course of the past several months, it doesn't look like it's going anywhere - on a net basis - anytime.

Top 10 Promising Stocks To Watch For 2014: Roche Holding AG (ROG.VX)

Roche Holding AG is a Swiss pharmaceuticals and diagnostics holding company. It belongs to the Roche Group that operates through subsidiaries and associated companies around the world. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. The Company has two divisions: Pharmaceuticals and Diagnostics. Pharmaceuticals are divided into two sub-divisions: Roche Pharmaceuticals and Chugai. It operates in the United States, Western Europe, Japan, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Asia-Pacific and Other regions. Diagnostics include five business areas: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. It operates in five geographical regions: Europe, Middle East and Africa (EMEA); North America; Asia-Pacific; Latin America, and Japan. Advisors' Opinion:

• [By Lauren Pollock]

  Roche Holding AG(ROG.VX) has entered a pact with Prothena Corp.(PRTA) PLC to develop and commercialize a treatment the clinical-stage biotechnology firm is developing for Parkinson’s disease. In after-hours trading, Prothena’s stock rose 8.6% to $29.75 premarket.

Top 10 Promising Stocks To Watch For 2014: Stanley Black & Decker Inc.(SWK)

Stanley Black & Decker, Inc. manufactures tools and engineered security solutions worldwide. The company?s Security segment provides a range of mechanical and electronic security products and systems, as well as various security services consisting of security integration systems, software, and related installation, maintenance, monitoring services; automatic doors, door closers, and exit devices; healthcare storage and supply chain solutions; patient protection products; hardware; and locking mechanisms. This segment sells its products to retailers; educational, financial, and healthcare institutions; and commercial, governmental, and industrial customers through direct sales forces and third party distributors. Its Industrial segment offers mechanics tools and storage systems, including wrenches, sockets, electronic diagnostic tools, tool boxes, and industrial storage and retrieval systems; engineered healthcare storage and retrieval systems; hydraulic tools and accessor ies; plumbing, heating, and air conditioning tools; assembly tools and systems; and specialty tools. This segment sells its products to industrial customers through third party distributors and direct sales forces. The company?s Construction & Do-It-Yourself segment manufactures hand tools, including measuring and leveling tools, planes, hammers, demolition tools, knives and blades, saws, chisels, and consumer tackers; consumer mechanics tools; storage units comprising plastic and metal tool boxes; and pneumatic tools and fasteners for use in construction, remodeling, furniture making, pallet and manufacturing applications. This segment sells its products to professional end users and consumers through retailers, including home centers, mass merchants, hardware stores, and retail lumber yards. The company was formerly known as The Stanley Works and changed its name to Stanley Black & Decker, Inc. in March 2010. Stanley Black & Decker was founded in 1843 and is based in New B ritain, Connecticut.

Advisors' Opinion:

• [By Monica Gerson]

  Stanley Black & Decker (NYSE: SWK) is estimated to report its Q3 earnings at $1.38 per share on revenue of $2.82 billion.

  Bank of America (NYSE: BAC) is projected to report its Q3 earnings at $0.18 per share on revenue of $22.03 billion.

• [By Jim Jubak]

  Blankfein's less than confident tone, of course, raises that issue at Goldman, but you can see it even more clearly in Stanley Black & Decker's (SWK) third quarter report from October 16, before the market opened in New York. On the news, the shares fell 14.25% on the day, as the company missed on revenue for the quarter, and then lowered guidance for the full 2013 year that ends with the December quarter. The new guidance looks for earnings per share of $4.90 to $5.00, well below the company's previous guidance of $5.40 to $5.65.

• [By Rich Smith]

  This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature a pair of downgrades, for toolmaker Stanley Black & Decker (NYSE: SWK  ) and electrical equipment maker EnerSys (NYSE: ENS  ) alike. But the news isn't all bad, so before we address those two, let's take a look at why one analyst thinks that...

Top 10 Promising Stocks To Watch For 2014: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Advisors' Opinion:

• [By Matt Egan]

  Shares of Hemispherx Biopharma (HEB) soared 11% on Wednesday amid the rising Ebola fears. Earlier this week, the company announced a series of research collaborations aimed at developing treatments to fight Ebola.

• [By MONEYMORNING]

  Hemispherix Biopharma Inc. (NYSE: HEB) is a specialty pharmaceutical company. It engages in the clinical development of new drug therapies based on natural immune system enhancing technologies and targets the treatment of viral and immune-based clinical disorders. The Philadelphia, Pa.-headquartered company gained widespread attention over the last several months for its work on flu research. Its flagship products include Alferon N Injection, approved by the FDA for a category of sexually transmitted disease infection. Experimental treatments include Ampligen and Oragens, in development stages for the potential treatment of global viral diseases and disorders of the immune system including human papilloma virus, human immunodeficiency virus, chronic fatigue syndrome, hepatitis, and influenza. Shares have traded as low as $0.18 and as high as $0.55 over the last year. At last check, shares were changing hands around $0.50 on volume of 2 million shares.